Rapamycin, Metformin, and TPE: Can You Combine Longevity Protocols Safely?

Anyone active in longevity communities online has seen the stack posts: a list of five, ten, sometimes fifteen compounds and interventions someone is self-administering, often assembled from podcast mentions, research papers read in isolation, and forum consensus rather than any individualized medical review. Rapamycin, metformin, and therapeutic plasma exchange are three of the most frequently mentioned interventions in these stacks, and they are also three of the interventions most often combined without anyone actually checking whether the combination makes physiological sense or carries risk.

This is the actual review process a physician should walk through before signing off on combining them, laid out so you can see where the real questions are.

Step One: What Each Intervention Is Actually Targeting

Before any combination is evaluated, it matters to be precise about what each of these three is doing, because "longevity" is not a single mechanism and stacking things aimed at different pathways is a very different decision than stacking things aimed at the same one.

Rapamycin, an mTOR inhibitor originally developed as an immunosuppressant for transplant patients, is used in longevity contexts at low, intermittent doses to inhibit the mTOR pathway, a cellular growth and metabolism pathway implicated in aging in animal models. Metformin, a decades-old diabetes medication, affects glucose metabolism and has several proposed longevity mechanisms including AMPK activation and effects on mitochondrial function, and is being studied specifically for its potential effects independent of diabetes status. TPE removes and replaces plasma to reduce circulating factors including certain inflammatory proteins and accumulated environmental compounds, working at the level of what's circulating in the blood rather than at a cellular signaling pathway.

The key point: these are not redundant interventions targeting the same mechanism, which is actually one argument in favor of a combined approach being physiologically sensible rather than simply piling on more of the same thing. It is also exactly why each needs to be evaluated on its own safety profile before being layered with the others.

Step Two: Rapamycin and Metformin Together

This is the combination most frequently discussed in longevity circles, and it has a specific, legitimate point of physiological tension worth understanding rather than glossing over. Some preclinical research has suggested metformin may, under certain conditions, activate mTOR through indirect pathways in some tissue types, which on paper sits in some tension with rapamycin's role as an mTOR inhibitor. In practice, most physicians working in this space consider the combination reasonable when dosed appropriately and monitored, but "reasonable in principle" is not the same as "safe to combine without any physician involvement," particularly because both medications carry their own independent risks that need individual management.

Rapamycin's risks in intermittent, low-dose longevity protocols include mouth sores, changes in lipid panels, and in some cases temporary immune suppression that warrants monitoring, particularly around any planned surgery, vaccination, or acute illness. Metformin's risks include gastrointestinal side effects, a rare but serious risk of lactic acidosis in patients with kidney impairment, and vitamin B12 deficiency with long-term use, which requires periodic lab monitoring on its own regardless of what else is in the stack.

What this means practically: combining these two without baseline and follow-up labs, specifically kidney function, lipid panel, complete blood count, and B12 levels, is not a reasonable combination, regardless of what protocol you've read about online. With that monitoring in place and a physician managing dosing intervals, many patients can reasonably use both.

Step Three: Adding TPE Into the Mix

TPE introduces a different category of consideration because it is not a daily or weekly medication but a periodic procedure, and the interaction question isn't primarily about the biochemistry of rapamycin or metformin directly reacting with plasma exchange. It's about timing and about what plasma exchange does to circulating drug and protein levels more broadly.

Because TPE removes and replaces a substantial volume of plasma in a single session, it can meaningfully reduce circulating levels of protein-bound medications and compounds at the time of the procedure. This matters practically in one specific way: if you are on a stable, consistent dosing schedule for rapamycin or metformin, a TPE session may transiently affect circulating levels of these and other medications, which is a reason to schedule the two around each other rather than treating them as unrelated events happening to occur in the same month. It is also a reason immune status should be reviewed prior to TPE if rapamycin is part of your regimen, given rapamycin's immune-modulating effects and the fact that TPE itself can transiently reduce certain circulating immune factors.

What this means practically: TPE sessions should be scheduled with your treating physician's awareness of your current medication stack, not booked independently as though it exists in isolation from what else you're taking. This is precisely the coordination gap that causes problems when patients self-administer stacks assembled from multiple, non-communicating sources, a compounding pharmacy for rapamycin, a primary care doctor prescribing metformin off-label, and a separate longevity clinic for TPE, none of whom are talking to each other.

Step Four: The Monitoring Plan That Actually Makes a Combined Stack Reasonable

Assuming all three interventions have been individually deemed appropriate for you, a physician managing the combination as a coordinated protocol, rather than three separate, disconnected relationships, would typically want baseline labs before starting anything, including kidney and liver function, a complete metabolic panel, lipid panel, complete blood count, and inflammatory markers, followed by scheduled reassessment at intervals appropriate to each intervention, generally more frequent in the first several months and less frequent once a stable pattern is established.

This is also where pre- and post-treatment labs around TPE specifically become relevant to the broader stack, not just to TPE in isolation, since they provide a window into how your body is responding to the combined regimen, not just to plasma exchange on its own.

Step Five: The Honest Caveat

None of this should be read as a blanket endorsement of combining all three. The research base for rapamycin and metformin as longevity interventions in otherwise healthy adults, independent of their original approved indications, is still developing, largely built on preclinical and observational data rather than large randomized trials specifically measuring lifespan or healthspan outcomes in humans. TPE's longevity-specific evidence base, while growing, including the Buck Institute-associated trial data on biological age markers, is also still early relative to its established medical uses for other conditions. Combining three interventions each individually still building out its human evidence base compounds uncertainty, even when each one is individually reasonable and even when interactions between them are manageable.

The right way to think about this isn't "is this combination safe or dangerous" as a yes or no question. It's "is there a physician actively coordinating my labs, my dosing, and my scheduling across all three, and am I being honest with myself about the fact that the evidence for the combined approach, specifically, is thinner than the evidence for any one piece alone."

Step Six: What Happens When You Add a Fourth or Fifth Compound

The three interventions discussed so far are common enough that they warrant a dedicated review, but longevity stacks in the wild rarely stop at three. NAD+ precursors, peptide therapies, various supplements marketed around inflammation or mitochondrial support, and in some cases additional prescription medications used off-label are frequently added on top of a rapamycin-metformin-TPE base, often incrementally over months as a person reads more, joins more forums, and accumulates more recommendations.

Each addition to a stack doesn't just add its own individual risk profile, it also increases the total number of pairwise interactions that need to be considered, and the number of variables that make it harder to identify what's actually responsible if something changes, whether that's a positive change in how you feel or an unexpected lab abnormality. This is a genuinely underappreciated problem in self-directed longevity protocols. If your lipid panel shifts unexpectedly, and you're taking rapamycin, metformin, an NAD+ precursor, and a peptide, and receiving periodic TPE, isolating which variable is responsible, or whether it's an interaction between two or more of them, becomes very difficult without a physician who has been tracking your labs against a documented timeline of when each element was introduced or adjusted.

This is a strong argument for introducing new elements to a stack one at a time, with adequate monitoring between additions, rather than assembling a full protocol all at once based on a reading list. It is also an argument for working with a single coordinating physician who maintains that timeline on your behalf, since most patients, understandably, don't maintain this level of documentation on their own over months or years.

Step Seven: Recognizing When to Pause or Simplify a Stack

Part of managing a combined protocol responsibly is having a clear plan for when to pause or scale back, not just when to add. If lab work shows a concerning trend, elevated liver enzymes, a meaningful shift in kidney function, or lipid changes outside expected ranges, the appropriate response is typically to isolate the variable by pausing the most recently added or most plausible contributing element, rather than pausing everything at once or, conversely, continuing everything unchanged while hoping the next lab draw looks better.

This kind of clear-headed troubleshooting is much easier when there's a single physician managing the whole picture from the start, since they'll have both the documented timeline and the clinical judgment to make a reasoned call about what to adjust first, rather than a patient trying to reverse-engineer the answer from forum posts written by people with different baseline health, different doses, and different combinations entirely.

Why This Requires Coordinated, Concierge-Level Care Rather Than DIY Stacking

The pattern that causes real problems in longevity medicine isn't usually one intervention taken responsibly. It's multiple interventions sourced from different, non-communicating providers, self-dosed based on forum consensus, without shared lab data or a single physician who has visibility into the full picture. A concierge model, where one physician has oversight of your full stack, your lab trends over time, and the timing of periodic interventions like TPE relative to your daily medications, is specifically designed to close that gap.

Why Physicians Are Often More Cautious About This Combination Than Online Communities

There is a noticeable gap between how confidently combined stacks are discussed in longevity forums and how much more cautiously most physicians, including those who specialize in longevity medicine and are personally enthusiastic about the underlying science, tend to approach the same combinations in an actual clinical setting. This gap is worth understanding rather than dismissing as physicians simply being overly conservative or behind on the latest research.

Forums tend to aggregate anecdotal success stories and self-reported outcomes, which are useful for generating hypotheses but are not equivalent to controlled data, and they rarely surface the cases where something went wrong, since patients experiencing an adverse effect are less likely to post a detailed account than patients who feel their stack is working well. Physicians, on the other hand, are trained to weigh the actual strength of evidence behind an intervention, consider the individual patient's full health picture rather than a generalized protocol, and take seriously the asymmetry between a stack that helps and a stack that causes a preventable, sometimes serious, adverse event.

This doesn't mean physician caution is always correctly calibrated either. Medicine has a long history of being slow to adopt genuinely beneficial interventions supported by real evidence. But the appropriate response to that history isn't to disregard physician oversight in favor of self-directed protocols, it's to work with a physician who takes emerging longevity research seriously, engages honestly with what is and isn't yet well-established, and is willing to build an individualized, monitored plan rather than either dismissing the science entirely or endorsing every combination uncritically.

A Realistic Picture of What Coordinated Onboarding Looks Like

For a patient arriving at Liondale Medical with an existing interest in combining these interventions, or already partway into a self-assembled stack from other sources, a coordinated onboarding process typically starts with a full accounting of everything currently being taken or done, including supplements many patients don't think to mention because they don't consider them "medications." This is followed by comprehensive baseline labs covering the panels discussed above, a physician review of the full picture against your specific health history and goals, and a specific, written plan covering dosing, timing relative to any planned TPE sessions, and a defined schedule for follow-up labs.

This process typically takes longer than patients expect for an initial visit, precisely because getting it right the first time, rather than making adjustments reactively after something goes wrong, is the entire value proposition of a coordinated, physician-led approach over a self-directed one. Patients who come in expecting to simply confirm a stack they've already researched are sometimes surprised to have specific elements questioned or adjusted, and that's exactly the intended function of the process, not a formality to move past quickly.

Frequently Asked Questions

Is it dangerous to combine rapamycin and metformin?

Not inherently, but it requires physician oversight and regular lab monitoring, since both carry individual risks and there is some theoretical interaction at the level of the mTOR pathway that warrants informed dosing decisions.

Can I get TPE while taking rapamycin or metformin?

Yes, but the timing should be coordinated with your physician, since TPE can transiently affect circulating levels of medications and, in the case of rapamycin, immune status should be reviewed beforehand.

What labs should I have before starting a combined longevity protocol?

Typically kidney and liver function, a complete metabolic panel, lipid panel, complete blood count, B12 levels, and inflammatory markers, repeated at intervals throughout the protocol.

Is there strong human evidence that this combination extends lifespan?

Not yet at the level of large randomized human trials specifically measuring lifespan outcomes. The evidence for each intervention individually is more developed than the evidence for the combined stack.

Why can't I just source these separately and manage the combination myself?

Because none of your separate providers, a compounding pharmacy, a primary care doctor, and an independent clinic, will have full visibility into your combined labs, dosing, and timing, which is exactly where interaction risks and monitoring gaps occur.

How often should labs be repeated once I'm stable on a combined protocol?

This varies by individual risk factors and response, but is typically more frequent in the first several months and can be spaced out once a stable, well-tolerated pattern is established, determined by your physician.

This page was written and medically reviewed by Lionel Bissoon, D.O., founder of Liondale Medical. Dr. Bissoon is a board-certified osteopathic physician specializing in anti-aging and concierge medicine on the Upper West Side of Manhattan.

This content is for educational purposes only and does not constitute medical advice. Individual results may vary. Consult a qualified physician before beginning any new treatment.

Published August 18th, 2026